Abstract 401P
Background
Academic field in oncology is male dominated in India as it is in the rest of the world. There is a dearth of female oncologists in managerial or leadership posts in oncology. Female oncologists face unique challenges in this field. Female authorship as first or corresponding author is a surrogate marker for the representation of females in the academic world. This study was undertaken to determine the extent of female participation/leadership in oncology in India.
Methods
An online survey was conducted across the women in the field of oncology in India. Also, the issues of Indian Journal of Cancer and Indian Journal of Medical and Paediatric Oncology from January 2017 to December 2018 were examined. The articles with female first or corresponding authors were enumerated.
Results
Of the 153 participants in the survey, 56% were above 40 years of age. 53% of them were clinical oncologists. 65% of the females worked in male majority teams and 67% admitted to working with male managers. Only 31% of the respondents covered a leadership role within their jobs. Family commitments, perception of males as the natural leaders and maintaining a work family balance were quoted to be the most frequent obstacles to career progression. A total of 558 journal publications were inspected. Of these, 145 articles (26%) had a female first author or a corresponding author, of which 94 (64.9%) were original articles. Each issue had a median of 30 publications, of which median of 8 publications (range 3-15) were authored by females. Of the 360 original articles perused, only 94 (26.1%) had female authorship.
Conclusions
This study was undertaken to analyse the participation of females in oncology and allied sciences in India. Only 1/3 of the females were in a leadership position of the 153 survey participants. Majority of the females work in male-dominated work environments and tackle multitude of impediments in advancement in their profession. Objectively, only 26% of the publications in two of the leading oncology journals of India were authored by females. Female first/corresponding authors were found only in 26% of the original articles. More efforts are to be taken for women empowerment and increase the representation of females in this field. More flexible work/training schedules are required for their upliftment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract